文献速递肿瘤 PET/CT

欧洲泌尿外科学会生化复发风险分组可预测根治性前列腺切除术后PSMA PET表现

The European Association of Urology Biochemical Recurrence Risk Groups Predict Findings on PSMA PET in Patients with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy.
PubMed 文献 · J Nucl Med · 2021-07-29

该研究汇总两项前瞻性研究共145例根治性前列腺切除术后生化复发患者,按欧洲泌尿外科学会生化复发风险分组评估PSMA靶向PET/CT阳性率。高危组阳性率82.0%显著高于低危组48.9%,高危分组为PSMA PET/CT阳性的独立预测因素(OR 6.73),风险分组联合PSA的AUC高于单用PSA(0.834 vs 0.759)。

要点

  • 高危生化复发患者PSMA PET/CT阳性率82.0%,低危组48.9%
  • 高危分组为PSMA PET/CT阳性的独立预测因素,OR 6.73
  • 风险分组联合PSA的AUC 0.834,优于单用PSA的0.759

核心结论

  • 欧洲泌尿外科学会生化复发风险分组可界定生化复发时最可能从PSMA PET/CT扫描中获益的候选患者。

研究设计与样本

  • 汇总两项纳入生化复发患者的前瞻性研究,共145例患者,其中低危45例、高危100例。
  • 按欧洲泌尿外科学会生化复发风险类别对患者进行分组,采用逻辑回归进行单变量和多变量分析。

主要发现

  • 高危生化复发患者PSMA PET/CT阳性率高于低危患者(82.0% vs. 48.9%;P < 0.001)。
  • 多变量逻辑回归中高危分组达到PSMA PET/CT阳性结果的独立预测因素地位(OR 6.73;95%CI 2.41-18.76;P < 0.001)。
  • 生化复发风险分组联合前列腺特异性抗原的曲线下面积高于单用前列腺特异性抗原(0.834 vs. 0.759,P = 0.015)。

关键数值与推荐

  • 生化复发风险分组联合PSA的AUC为0.834,单用PSA的AUC为0.759(P = 0.015)。
  • 高危分组预测PSMA PET/CT阳性的OR为6.73(95%CI 2.41-18.76;P < 0.001)。

临床怎么用

  • 对根治性前列腺切除术后生化复发患者,可依据欧洲泌尿外科学会风险分组联合PSA筛选适合行PSMA PET/CT扫描的候选者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Our purpose was to evaluate the association of a new biochemical recurrence (BCR) risk stratification system with PSMA-targeted PET/CT findings. Methods: Two prospective studies that included patients with BCR were pooled. Findings on PSMA PET were catalogued. Patients were characterized according to the European Association of Urology BCR risk categories. Univariable and multivariable analyses were performed by logistic regression. Results: In total, 145 patients were included (45 low-risk and 100 high-risk). High-risk BCR patients had a higher positive rate than low-risk patients (82.0% vs. 48.9%; P < 0.001) and reached independent predictor status for positive PSMA PET/CT scan results on multivariable logistic regression (odds ratio, 6.73; 95% CI, 2.41-18.76; P < 0.001). The area under the curve using the combination of BCR risk group and prostate-specific antigen was higher than that using prostate-specific antigen alone (0.834 vs. 0.759, P = 0.015). Conclusion: The European Association of Urology BCR risk groups define the candidates who can most benefit from a PSMA PET/CT scan when BCR occurs.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Dong L, Su Y, Zhu Y, et al. The European Association of Urology Biochemical Recurrence Risk Groups Predict Findings on PSMA PET in Patients with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy. J Nucl Med. 2021. PMID: 34326128. doi:10.2967/jnumed.121.262411

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。